Recently, novel glucose-lowering agents (GLAs), namely glucagon-like peptide-1 receptor agonists (GLP-1RAs) [11,12,13] and sodium-glucose cotransporter 2 inhibitors (SGLT2is) [14, 15], were shown to improve liver fibrosis-related biomarkers such as alanine aminotransferase (ALT), visceral adipose tissue volume, and liver fat content
PMID: 256
Companies that market compounded drugs combining, mixing or altering drug ingredients have prospered amid shortages of the class of weight-loss medications, called GLP-1 (glucagon-like peptide-1) receptor agonists
Read the full Alpha-lipoic Acid + Abrocitinib interaction Acalabrutinib Calquence How Acalabrutinib interacts with Nerve Shield through 4 ingredients
It is crucial to emphasise that probiotics are not a treatment for the underlying conditions requiring GLP-1 therapy , nor are they proven to prevent or eliminate GLP-1-related side effects
In 2024, SAXENDA generated sales of USD 345 million in the US